Brainteaser
Brainteaser is an EU Horizon 2020-funded research consortium (2020–2025) that built AI/ML models, federated learning infrastructure, and patient/clinician apps to predict disease progression in ALS and MS, serving clinical institutions and patients across Italy, Portugal, and Spain.
- Company typePrivate
- Founded2020
- HeadquartersEstremera, Spain
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Brainteaser does
Brainteaser is a European Union Horizon 2020-funded data science research project (grant agreement No GA101017598) that ran from 2020 to June 2025, coordinated by Universidad Politécnica de Madrid with scientific coordination from the University of Padova. It developed artificial intelligence and machine learning tools to support patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and the clinicians who treat them, combining large curated clinical datasets from institutions in Italy, Portugal, and Spain with daily sensor data from a Patient App, environmental exposure data, and a project-developed ontology for standardization. Its technical outputs include AI models for patient stratification, prognosis prediction, and disease progression simulation; a Patient App and a Healthcare Professional App co-designed with end users; a federated learning infrastructure enabling privacy-preserving cross-institutional model training; and curated shared datasets covering approximately 2,250 ALS patients (7,536 visits) and 1,800 MS patients.
The project operated as a research consortium rather than a commercial enterprise, with no product pricing, no commercial sales channel, and revenue derived entirely from the EU Horizon 2020 grant. Its go-to-market motion was community-led, anchored by the annual iDPP@CLEF open evaluation challenges (2022–2024) under the CLEF Initiative, joint webinars with peer projects (Lethe, HEREDITARY), alignment with pan-European initiatives (Precision ALS, MND-SWIFTT, ENCALS), and open-access publication of datasets, deliverables, and AI models for the research community. The project formally concluded on June 3, 2025, at a final event co-located with the ENCALS 2025 conference in Turin, Italy, transitioning its outputs to an open-science legacy with InSilicoTrials Technologies engaged to explore post-project sustainability.
Brainteaser firmographics
Firmographics- Name
- Brainteaser
- Legal name
- Brainteaser
- Website
- https://brainteaser.health
- Company type
- Private
- Founded year
- 2020
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- Brainteaser is an EU Horizon 2020-funded research consortium (2020–2025) that built AI/ML models, federated learning infrastructure, and patient/clinician apps to predict disease progression in ALS and MS, serving clinical institutions and patients across Italy, Portugal, and Spain.
- Ownership category
- akta.pro rank
Brainteaser industry classification
Industry- Product category
- Healthcare AI Research
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology Telemedicine Platforms (HLALAGAC)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Healthcare & Wellness Personalization (HDAAAGAI)
Keywords
Where Brainteaser is headquartered
LocationHeadquarters
- HQ city
- Estremera
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
Brainteaser business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Research Grant Funding: BRAINTEASER is funded under the European Union's Horizon 2020 research and innovation programme under grant agreement No GA101017598. This is a grant-funded research project, not a commercial enterprise generating revenue from products or services.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Brainteaser product offering
Product offeringCore offering
Brainteaser is a Horizon 2020-funded data science research project that develops AI and machine learning tools to support patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and their clinicians. The project delivers a Patient App and Healthcare Professional App for remote sensor-based monitoring, AI models for disease progression prediction and patient stratification, and openly available curated datasets built from clinical, lifestyle, environmental, and sensor data collected across Italy, Portugal, and Spain.
Product overview
BRAINTEASER is a Horizon 2020-funded data science project that functions as a research platform rather than a commercial product. It combines a Patient App and Healthcare Professional App with AI models for disease progression prediction in ALS and MS patients. The project also organizes the annual iDPP@CLEF open evaluation challenges and provides shared datasets for the research community. Technical solutions follow agile, user-centered approaches integrating cost-efficient sensors, clinical data, and environmental data to support precision medicine for neurodegenerative diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Patient App A mobile application co-designed with end users for patients with ALS and MS to track health data, submit self-assessments (such as ALSFRS-R questionnaires), and enable remote sensor-based monitoring of disease progression.
- Healthcare Professional App A clinical application for neurologists and clinicians treating ALS and MS patients that supports patient monitoring, AI-generated disease progression predictions, and access to integrated datasets for patient management and care decisions.
- BRAINTEASER AI Disease Progression Models Machine learning models developed for patient stratification, prognosis prediction, and disease progression simulation in ALS and MS patients, using integrated clinical datasets, sensor data, and environmental exposures.
- iDPP@CLEF Challenge Annual open evaluation challenge series (2022-2024) providing datasets and evaluation infrastructure for AI researchers to develop and benchmark intelligent disease progression prediction algorithms for ALS and MS under the CLEF Initiative umbrella.
- BRAINTEASER Shared Datasets Highly curated datasets built from a project-developed ontology, including ALS clinical data from ~2,250 patients and MS data from ~1,800 patients with longitudinal follow-up, wearable sensor readings, environmental and pollution data, collected from institutions in Italy, Portugal, and Spain.
Quantifiable outcome
- AI models developed for patient stratification, prognosis prediction, and disease progression simulation for ALS and MS
- +2 more outcomes
Companies that use Brainteaser
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Brainteaser technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
Brainteaser partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and moderate.
- Lethe ProjectminorJoint webinar on federated learning for neurodegenerative disease research conducted in 2025. Both projects share methodologies for privacy-preserving machine learning approaches.
- HEREDITARY ProjectminorJoint webinar on federated learning conducted with Brainteaser and Lethe projects. Collaboration on advancing AI models for neurodegenerative disease research.
- Precision ALSmoderatePan-European initiative using AI to accelerate clinical research. Alignment at ENCALS 2025 conference for cross-project dialogue on AI in neurology and digital health.
- MND-SWIFTTminorWorking group promoting digital technologies in motor neuron disease research and care. Sessions aligned at ENCALS 2025 for cross-project collaboration.
- ENCALS (European Network to Cure ALS)moderateENCALS 2025 Meeting hosted the BRAINTEASER final event as a satellite session. Premier annual gathering of European ALS researchers.
- InSilicoTrials TechnologiesminorCompany represented by Vincenzo Carbone, PhD, who outlined strategies for ensuring sustainability and future uptake of BRAINTEASER's tools post-project.
- Global Health ConnectorminorOrganization represented by Natalia Allegretti who chaired the final event. Contributed to project dissemination and community engagement.
- CLEF InitiativemoderateConference and Labs of the Evaluation Forum - internationally renowned campaign series. BRAINTEASER organizes its open evaluation challenges (iDPP@CLEF) under the CLEF Initiative umbrella, providing scientific soundness and international reach.
Scale indicators6 records
Recent moves6 records
Expansion highlights3 records
Brainteaser competitors and assessment
Company assessmentDirect peers
- HEREDITARY Project: Sister EU Horizon 2020 project on AI for neurodegenerative disease research. Collaborates with Brainteaser on federated learning webinars and shares methodology for privacy-preserving machine learning across institutions.
- Precision ALS: Pan-European initiative applying AI to accelerate ALS clinical research, directly named partner at ENCALS 2025. Comparable in disease focus (ALS), AI methodology, and pan-European institutional structure to Brainteaser.
- MND-SWIFTT: Working group promoting digital technologies in motor neuron disease research and care, aligned with Brainteaser at ENCALS 2025. Direct overlap in MND/ALS focus, digital health tooling, and European research-community scope.
- Lethe Project: Sister EU Horizon 2020 project developing federated learning and AI for dementia and cognitive decline. Direct methodological overlap with Brainteaser's federated learning architecture, privacy-preserving multi-institution AI, and neurodegenerative disease focus (joint webinar collaboration).
Broad incumbents
- Tempus Labs: AI-driven precision medicine platform integrating multi-modal clinical and molecular data at scale. Comparable in AI-driven clinical decision support and patient stratification but covers a broader disease portfolio including oncology, with established commercial deployment capabilities.
- Owkin: Commercial leader in federated learning for healthcare AI across multiple therapeutic areas including oncology and cardiovascular. Direct technological overlap with Brainteaser's federated learning infrastructure, but operates as a funded commercial entity with a broader disease portfolio (shared methodology).
Others
- InSilicoTrials Technologies: AI and in-silico modeling company for clinical trials, explicitly named Brainteaser partner (Vincenzo Carbone) outlining strategies for post-project sustainability and uptake of BRAINTEASER tools. Adjacent rather than directly competitive.
- ENCALS (European Network to Cure ALS): European network of ALS researchers and clinicians hosting the ENCALS 2025 meeting that served as Brainteaser's final event venue. Scientific community convening body rather than a competing technology provider; relevant ecosystem participant.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Brainteaser social profiles
Digital presenceBrainteaser compliance and trust
Trust signalCompliance2 records
Brainteaser financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brainteaser leadership team
Management profileNumber of profiles
Brainteaser funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brainteaser M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brainteaser
What does Brainteaser do?
Brainteaser is a Horizon 2020-funded data science research project that develops AI and machine learning tools to support patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and their clinicians. The project delivers a Patient App and Healthcare Professional App for remote sensor-based monitoring, AI models for disease progression prediction and patient stratification, and openly available curated datasets built from clinical, lifestyle, environmental, and sensor data collected across Italy, Portugal, and Spain.
Is Brainteaser a public or private company?
Brainteaser is a private company. It is classified as nonprofit foundation owned and is currently closed.
When was Brainteaser founded?
Brainteaser was founded in 2020. It employs 11 to 50 people.
Where is Brainteaser based?
Brainteaser is headquartered in Estremera, Spain, in the Europe region.
How does Brainteaser make money?
One revenue line is on record: research Grant Funding.
Who are Brainteaser's main competitors?
Direct peers on record are HEREDITARY Project, Precision ALS, MND-SWIFTT and Lethe Project. Broad incumbents are Tempus Labs and Owkin. Others are InSilicoTrials Technologies and ENCALS (European Network to Cure ALS).
Does Brainteaser have an API?
No public API is recorded for Brainteaser.
What industry is Brainteaser in?
Brainteaser's product category is Healthcare AI Research. Its primary akta.pro industry code is HLALAGAC, Neurology Telemedicine Platforms, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5417 and its SIC code is 8731.